Current patient-facing overview describing GcMAF theory, research problems, retractions, lack of approval, and online sales concerns.
GcMAF
Gc protein-derived macrophage activating factor (GcMAF) is a proposed macrophage-activating immunotherapy linked to cancer through the vitamin D-binding protein/nagalase hypothesis. The cancer record is controversial and disputed: it includes lab and animal studies, small human reports, retractions, critiques, regulatory actions, and ongoing claims from proponents.
Preprint-style record suggesting vitamin D may regulate GC protein abundance and tumor engraftment in models.
Critical overview revisiting Yamamoto GcMAF research and debate around retracted studies.
Production-method paper presenting a way to prepare high-quality GcMAF for functional analysis and clinical testing.
BMJ news item summarizing David Noakes case and GcMAF sold as a fake cancer cure.
MHRA press release on David Noakes, Immuno Biotech, unlicensed GcMAF manufacture/sale, and cancer-cure claims.
Anticancer Fund overview calling GcMAF cancer-cure claims unsupported and exploitative, with discussion of retractions.
Glycan structure of Gc Protein-derived Macrophage Activating Factor as revealed by mass spectrometry
Mass spectrometry paper defining glycan structure questions around GcMAF.
Preclinical study relevant to chemotherapy-associated oxaliplatin neuronal damage rather than direct cancer control.
Retraction notice for the metastatic colorectal cancer GcMAF paper.
Retraction notice for Yamamoto metastatic breast cancer GcMAF paper.
Anticancer Fund letter identifying serious inconsistencies and reliability problems in Yamamoto GcMAF cancer evidence.
Open-label uncontrolled retrospective report in 20 advanced cancer patients; authors note caution about cause-effect conclusions.
Lab study proposing GcMAF-induced macrophage stimulation can trigger apoptosis in human breast cancer cells.
In vitro/CAM assay paper reporting inhibition of MCF-7 proliferation, angiogenesis, and vimentin expression.
Mechanistic paper linking GcMAF to cAMP signaling and anti-angiogenic effects in CAM assay.
Cancer Research UK warns that GcMAF is not approved/licensed for cancer and lacks solid evidence for safety or effectiveness.
Small uncontrolled prostate cancer report claiming nagalase normalization and long recurrence-free follow-up.
Retracted Yamamoto paper claiming eradication of metastatic colorectal cancer based on nagalase normalization.
Retracted Yamamoto paper claiming metastatic breast cancer responses after weekly GcMAF and nagalase decline.
Study on salivary gland adenocarcinoma cell-derived alpha-NaGalase and inhibition of macrophage-activating factor bioactivity.
Study reporting electrophoretic differences and tumoricidal activity of GcMAF-treated macrophages.
Mouse study reporting DBP-MAF anti-angiogenic and tumor-growth inhibitory effects.
Early preparation/structural characterization study for GcMAF.
Biochemical study of alpha-NaGalase from tumor cell lines and its effect on GcMAF-mediated macrophage activation.
Animal study assessing GcMAF effects on survival time and serum NaGalase in Ehrlich ascites tumor-bearing mice.
Early paper proposing serum nagalase as a prognostic/immunosuppression marker in oral cancer patients.
Mouse SCCVII tumor model study of DBP-MAF as an adjunct to photodynamic therapy.